161 related articles for article (PubMed ID: 33211277)
1. Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS.
Maev IV; Kucheryavyy YA; Gubergrits NB; Bonnacker I; Shelest EA; Janssen-van Solingen GP; Domínguez-Muñoz JE
Drugs R D; 2020 Dec; 20(4):369-376. PubMed ID: 33211277
[TBL] [Abstract][Full Text] [Related]
2. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency.
Löhr JM; Hummel FM; Pirilis KT; Steinkamp G; Körner A; Henniges F
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1024-31. PubMed ID: 19352190
[TBL] [Abstract][Full Text] [Related]
3. In vitro Comparison of Pancreatic Enzyme Preparations Available in the Indian Market.
Shrikhande SV; Prasad VGM; Domínguez-Muñoz JE; Weigl KE; Sarda KD
Drug Des Devel Ther; 2021; 15():3835-3843. PubMed ID: 34522087
[TBL] [Abstract][Full Text] [Related]
4. Optimal size range for enteric-coated pancreatin preparations.
Lederer PC
Pancreas; 2011 Mar; 40(2):310-1. PubMed ID: 21311309
[No Abstract] [Full Text] [Related]
5. Comment on: "Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS".
Petersen KU
Drugs R D; 2021 Dec; 21(4):467-468. PubMed ID: 34669165
[No Abstract] [Full Text] [Related]
6. Author's Reply to Petersen: "Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS".
Maev IV; Kucheryavyy YA; Gubergrits NB; Bonnacker I; Shelest EA; Janssen-van Solingen GP; Dominguez-Munoz JE
Drugs R D; 2021 Dec; 21(4):469-470. PubMed ID: 34687428
[No Abstract] [Full Text] [Related]
7. Yarrowia lipolytica Lipase 2 Is Stable and Highly Active in Test Meals and Increases Fat Absorption in an Animal Model of Pancreatic Exocrine Insufficiency.
Aloulou A; Schué M; Puccinelli D; Milano S; Delchambre C; Leblond Y; Laugier R; Carrière F
Gastroenterology; 2015 Dec; 149(7):1910-1919.e5. PubMed ID: 26327131
[TBL] [Abstract][Full Text] [Related]
8. Characterization of all the lipolytic activities in pancreatin and comparison with porcine and human pancreatic juices.
Salhi A; Amara S; Mansuelle P; Puppo R; Lebrun R; Gontero B; Aloulou A; Carrière F
Biochimie; 2020 Feb; 169():106-120. PubMed ID: 31288050
[TBL] [Abstract][Full Text] [Related]
9. Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use.
O'Hare MM; McMaster C; Dodge JA
J Pediatr Gastroenterol Nutr; 1995 Jul; 21(1):59-63. PubMed ID: 8576816
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease.
Layer P; Keller J
J Clin Gastroenterol; 1999 Jan; 28(1):3-10. PubMed ID: 9916657
[TBL] [Abstract][Full Text] [Related]
11. In vitro dissolution profiles of enteric-coated microsphere/microtablet pancreatin preparations at different pH values.
Gan KH; Geus WP; Bakker W; Lamers CB; Heijerman HG
Aliment Pharmacol Ther; 1996 Oct; 10(5):771-5. PubMed ID: 8899086
[TBL] [Abstract][Full Text] [Related]
12. Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency.
Layer P; Gröger G
Digestion; 1993; 54 Suppl 2():10-4. PubMed ID: 7693530
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.
Morawski JH; Prüfert A; van Engen A; Foerster D; Sander-Struckmeier S; Małecka-Panas E; Pezzilli R
J Med Econ; 2012; 15 Suppl 1():15-25. PubMed ID: 23043594
[TBL] [Abstract][Full Text] [Related]
14. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency.
Piehl S; Brinkmann R; Windeck T
Eur J Gastroenterol Hepatol; 2010 May; 22(5):635-6; author reply 636-7. PubMed ID: 20393298
[No Abstract] [Full Text] [Related]
15. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension.
Seiler CM; Izbicki J; Varga-Szabó L; Czakó L; Fiók J; Sperti C; Lerch MM; Pezzilli R; Vasileva G; Pap A; Varga M; Friess H
Aliment Pharmacol Ther; 2013 Apr; 37(7):691-702. PubMed ID: 23383603
[TBL] [Abstract][Full Text] [Related]
16. Response to: properties of different pancreatin preparations used in pancreatic exocrine insufficiency, Löhr JM et al. Eur J Gastroenterol Hepatol 2009; 21(9):1024-1031.
Lederer PC
Eur J Gastroenterol Hepatol; 2010 May; 22(5):635; author reply 636-7. PubMed ID: 20393299
[No Abstract] [Full Text] [Related]
17. Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
Delhaye M; Meuris S; Gohimont AC; Buedts K; Cremer M
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):699-703. PubMed ID: 8853261
[TBL] [Abstract][Full Text] [Related]
18. The effect of enzyme substitution in patients with pancreatic insufficiency.
Worning H
Scand J Gastroenterol; 1980; 15(5):529-33. PubMed ID: 6160608
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pancreatin stability through enzyme activity determination.
Terra Gde P; Vinícius De Farias M; Trevisan MG; Garcia JS
Acta Pharm; 2016 Sep; 66(3):423-31. PubMed ID: 27383890
[TBL] [Abstract][Full Text] [Related]
20. [The effectiveness of pancreatic enzyme replacement therapy using microencapsulated pancreatin preparations in the correction of nutritional status in patients with chronic pancreatitis: a prospective observational study].
Bideeva TV; Maev IV; Kucheryavyy YA; Andreev DN; Shah YS; Lobanova EG; Zaborovskiy AV; Levchenko AI
Ter Arkh; 2020 Jan; 92(1):30-35. PubMed ID: 32598660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
